19 research outputs found
Expression of cell cycle proteins in male breast carcinoma
<p>Abstract</p> <p>Introduction</p> <p>Male breast cancer (MBC) is a rare, yet potentially aggressive disease. Although literature regarding female breast cancer (FBC) is extensive, little is known about the etiopathogenesis of male breast cancer. Studies from our laboratory show that MBCs have a distinct immunophenotypic profile, suggesting that the etiopathogenesis of MBC is different from FBCs. The aim of this study was to evaluate and correlate the immunohistochemical expression of cell cycle proteins in male breast carcinoma to significant clinico-biological endpoints.</p> <p>Methods</p> <p>75 cases of MBC were identified using the records of the Saskatchewan Cancer Agency over 26 years (1970-1996). Cases were reviewed and analyzed for the immunohistochemical expression of PCNA, Ki67, p27, p16, p57, p21, cyclin-D1 and c-myc and correlated to clinico-biological endpoints of tumor size, node status, stage of the disease, and disease free survival (DFS).</p> <p>Results</p> <p>Decreased DFS was observed in the majority of tumors that overexpressed PCNA (98%, p = 0.004). The overexpression of PCNA was inversely correlated to the expression of Ki67 which was predominantly negative (78.3%). Cyclin D1 was overexpressed in 83.7% of cases. Cyclin D1 positive tumors were smaller than 2 cm (55.6%, p = 0.005), had a low incidence of lymph node metastasis (38.2%, p = 0.04) and were associated with increased DFS of >150 months (p = 0.04). Overexpression of c-myc (90%) was linked with a higher incidence of node negativity (58.3%, p = 0.006) and increased DFS (p = 0.04). p27 over expression was associated with decreased lymph node metastasis (p = 0.04). P21 and p57 positive tumors were related to decreased DFS (p = 0.04). Though p16 was overexpressed in 76.6%, this did not reach statistical significance with DFS (p = 0.06) or nodal status (p = 0.07).</p> <p>Conclusion</p> <p>Aberrant cell cycle protein expression supports our view that these are important pathways involved in the etiopathogenesis of MBC. Tumors with overexpression of Cyclin D1 and c-myc had better outcomes, in contrast to tumors with overexpression of p21, p57, and PCNA with significantly worse outcomes. P27 appears to be a predictive marker for lymph nodal status. Such observation strongly suggests that dysregulation of cell cycle proteins may play a unique role in the initiation and progression of disease in male breast cancer. Such findings open up new avenues for the treatment of MBC as a suitable candidate for novel CDK-based anticancer therapies in the future.</p
The formation of human populations in South and Central Asia
By sequencing 523 ancient humans, we show that the primary source of ancestry in modern South Asians is a prehistoric genetic gradient between people related to early hunter-gatherers of Iran and Southeast Asia. After the Indus Valley Civilizationâs decline, its people mixed with individuals in the southeast to form one of the two main ancestral populations of South Asia, whose direct descendants live in southern India. Simultaneously, they mixed with descendants of Steppe pastoralists who, starting around 4000 years ago, spread via Central Asia to form the other main ancestral population. The Steppe ancestry in South Asia has the same profile as that in Bronze Age Eastern Europe, tracking a movement of people that affected both regions and that likely spread the distinctive features shared between Indo-Iranian and Balto-Slavic languages
Caratterizzazione archeometrica e archeologica della ceramica invetriata di et\ue0 islamica a Palermo (fine IX-met\ue0 XI secolo): nuovi dati e problemi aperti
In this article we will examine a series of problems that emerged during two systematic campaigns of archeometric analysis using optical and electronic microscopes to study the clays and, in particular, the glazes pertaining to 41 pottery samples datable to between the end of the 9th to the end of the 11th century which came from the stratigraphic sequences discovered in some excavations conducted in Palermo from the 1980s until 2000 (Castello-San Pietro; Gancia; Palazzo Bonagia). Despite the many archeometric studies focused on the petrographic definition of Palermitan pottery, no project has yet been directed to the systematic identification of the types of glazes used for this production, although in reality the specific study of these latter opens a whole new series of research possibilities that have important effects on the economic, social and methodological aspects. The technological definition of Palermitan pottery products is part of a wider context of the problems related to glazed ceramics in the Mediterranean area, consequently it is important to deal with them on an innovative basis which compares them with imports from North Africa and other contexts in the eastern areas. The technological characterization also requires a revision of the criteria used for classification which combines a chronological-typological approach with the archeometric data. \ua9 2020, Edizioni all'Insegna del Giglio s.a.s. All rights reserved
Recommended from our members
Synthesis and evaluation of nicotine alpha(4)beta(2) receptor radioligand, 5-(3 '-F-18-fluoropropyl)-3(2-(S)-pyrrolidinylmethoxy)pyridine, in rodents and PET in nonhuman primate
Nicotine alpha(4)beta(2) receptor subtypes are implicated in the study of Alzheimer's disease, schizophrenia, substance abuse, lung cancer, and other disorders. We report the development and evaluation of a putative antagonist, 5-(3'-fluoropropyl)-3-(2-(S)-pyrrolidinylmethoxy)pyridine (nifrolidine) as a PET agent for nicotine alpha(4)beta(2) receptors. Methods: In vitro binding affinity of nifrolidine was measured in rat brain slices labeled with I-125-iodoepibatidine or I-125-bungaratoxin. Selectivity of binding was measured in the presence of cytisine. F-18 radiolabeling was performed by reacting the tosylate precursor with F-18-fluoride followed by cleprotection. In vitro autoradiographic studies in rat brain slices with 5-(3'-F-18-fluoropropyl)-3-(2-(S)-pyrrolidinylmethoxy)pyridine (F-18-nifrolidine) were read on a phosphor imager. Rats were injected with F-18-nifrolidine (3.7 MBq each), and brain regions were counted at various times (2-120 min). Blocking studies were performed by subcutaneous injection of nicotine (10 mg/kg). A PET study of F-18-nifrolidine (approximately 148 MBq) was performed on an anesthetized rhesus monkey using a high-resolution scanner. Results: In vitro binding affinity of nifrolidine exhibited an inhibition constant of 2.89 nmol/L for the alpha(4)beta(2) sites. Radiosynthesis and high-performance liquid chromatography purifications yielded the product in approximately 20%-40% decay-corrected radiochemical yield to provide 18F-nifrolidine specific activities of approximately 111-185 GBq/mumol. In vitro autoradiography in rat brain slices revealed selective binding of F-18-nifrolidine to the anteroventral thalamic nucleus, ventral posteriomedial thalamus, dorsolateral geniculate, and, to a lesser extent, cortex and striata, which are known to contain alpha(4)beta(2) sites. This specific binding was completely abolished by 300 mumol/L nicotine. Ex vivo rat brain distribution studies indicated selective binding in the thalamus with a maximal thalamus-to-cerebellum ratio of approximately 3. The PET study revealed selective maximal uptake (0.01 % injected dose/mL) in regions of the thalamus (anteroventral and anteromedial mus, ventrolateral thalamus) and extrathalamic regions such as cingulate gyrus, lateral geniculate, temporal cortex, and frontal cortex. Conclusion: Binding of F-18-nifrolidine to alpha(4)beta(2) receptor-rich regions in rats and monkeys indicates promise as a PET agent. Additionally, the thalamus-to-cerebellum ratio approached a plateau of 1.7 in 120 min, indicating relatively faster kinetics compared with previously reported imaging agents
Ten-year results of accelerated hypofractionated adjuvant whole-breast radiation with concomitant boost to the lumpectomy cavity after conserving surgery for early breast cancer
Accelerated hypofractionated whole-breast radiotherapy (WBRT) is considered a standard therapeutic option for early breast cancer (EBC) in the postoperative setting after breast conservation (BCS). A boost to the lumpectomy cavity may further increase local control. We herein report on the 10-year results of a series of EBC patients treated after BCS with hypofractionated WBRT with a concomitant photon boost to the surgical bed over 4 weeks. Between 2005 and 2007, 178 EBC patients were treated with a basic course of radiotherapy consisting of 45 Gy to the whole breast in 20 fractions (2.25 Gy daily) with an additional boost dose of 0.25 Gy delivered concomitantly to the lumpectomy cavity, for an additional dose of 5 Gy. Median follow-up period was 117 months. At 10-year, overall, cancer-specific, disease-free survival and local control were 92.2% (95% CI 88.7â93.4%), 99.2% (95% CI 96.7â99.7%), 95.5% (95% CI 91.2â97.2%) and 97.3% (95% CI 94.5â98.9%), respectively. Only eight patients recurred. Four in-breast recurrences, two axillary node relapses and two metastatic localizations were observed. Fourteen patients died during the observation period due to other causes while breast cancer-related deaths were eight. At last follow-up, âĽG2 fibrosis and telangiectasia were seen in 7% and 5% of patients. No major lung and heart toxicities were observed. Cosmetic results were excellent/good in 87.8% of patients and fair/poor in 12.2%. Hypofractionated WBRT with concomitant boost to the lumpectomy cavity after BCS in EBC led to consistent clinical results at 10 years. Hence, it can be considered a valid treatment option in this setting
A Proof-of-Concept Analysis of Plasma-Derived Exosomal microRNAs in Interstitial Pulmonary Fibrosis Secondary to Antisynthetase Syndrome
Antisynthetase syndrome (ASSD) is an autoimmune disease characterized by the positivity of autoantibodies against different aminoacyl transfer RNA (tRNA) synthetases. Morbidity and mortality of this disease are highly affected by interstitial lung disease (ILD) which is present in about 80% of patients. In this study, we investigated possible differences in 84 immune-related circulating miRNAs between ASSD patients with and without ILD; we enrolled 15 ASSD patients, 11 with ILD (ILD+) and 4 without ILD (ILD-), and 5 patients with idiopathic pulmonary fibrosis (IPF) as an additional control group. All patients were at disease onset and not on therapy at the time of inclusion. Differentially expressed miRNAs were identified in plasma-derived exosomes, using an miRNA PCR array (MIHS-111ZG, Qiagen, Hilden, Germany); miR-30a-5p and miR-29c-3p were upregulated in ASSD-ILD patients compared to patients without lung involvement (adjusted p-value < 0.05). IPF patients showed higher miR-29c-3p expression levels with respect to both ASSD and ASSD-ILD (p = 0.0005), whereas levels of miR-30a-5p were not different. miR-29c-3p and miR-30a-5p are overexpressed in ASSD-ILD+ patients compared with ILDâ. These miRNAs are involved in the regulation of inflammation and fibrosis through their action on NF-ÎşB and TGF-β1. Although the mechanistic role of these miRNAs in ASSD-ILD development has to be elucidated, we suggest that their exosome levels could be useful in identifying patients at risk of ILD
Limiting Activity at β1-Subunit-Containing GABAA Receptor Subtypes Reduces AtaxiaSâ
GABAA receptor (R) positive allosteric modulators that selectively
modulate GABAARs containing β2- and/or
β3- over β1-subunits have been
reported across diverse chemotypes. Examples include loreclezole, mefenamic acid,
tracazolate, and etifoxine. In
general,âβ2/3-selectiveâ
GABAAR positive allosteric modulators are nonbenzodiazepines (nonBZs), do
not show Îą-subunit isoform selectivity, yet have anxiolytic efficacy with
reduced ataxic/sedative effects in animal models and humans. Here, we report on an
enantiomeric pair of nonBZ GABAAR positive allosteric modulators that
demonstrate differential β-subunit isoform selectivity. We have tested
this enantiomeric pair along with a series of other
β2/3-subunit selective, ι-subunit
isoform-selective, BZ and nonBZ GABAA positive allosteric modulators using
electrophysiological, pharmacokinetic, and behavioral assays to test the hypothesis
that ataxia may be correlated with the extent of modulation at
β1-subunit-containing GABAARs. Our findings provide
an alternative strategy for designing anxioselective allosteric modulators of the
GABAAR with BZ-like anxiolytic efficacy by reducing or eliminating
activity at β1-subunit-containing GABAARs